Mobile

A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004707-38

A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magnetic resonance imaging (MRI) defined poor risk rectal cancer

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the improvement in pathological complete response rate from the addition of cetuximab to neoadjuvant oxaliplatin and capecitabine followed by synchronous chemoradiation and total mesorectal excision in patients with magenetic resonance imaging (MRI) defined poor risk rectal cancer

Critère d'inclusion

  • Poor risk operable rectal adenocarcinoma

Liens